Cost-effectiveness of CBT, SSRI, and CBT+SSRI in the treatment for panic disorder.

OBJECTIVE: The objective of this study was to assess the cost-effectiveness of three empirically supported treatments for panic disorder with or without agoraphobia: cognitive behavioral therapy (CBT), pharmacotherapy using a selective serotonin reuptake inhibitor (SSRI), or the combination of both (CBT+SSRI). METHOD: Cost-effectiveness was examined based on the data from a multicenter randomized controlled trial. The Hamilton Anxiety Rating Scale was selected as a primary health outcome measure. Data on costs from a societal perspective (i.e., direct medical, direct non-medical, and indirect non-medical costs) were collected in the study sample (N=150) throughout a 24-month period in which patients received active treatment during the first twelve months and were seen twice for follow-up in the next twelve months. RESULTS: Total costs were largely influenced by costs of the interventions and productivity losses. The mean total societal costs were lower for CBT as compared to SSRI and CBT+SSRI. Costs of medication use were substantial for both SSRI and CBT+SSRI. When examining the balance between costs and health outcomes, both CBT and CBT+SSRI led to more positive outcomes than SSRI. CONCLUSION: Cognitive behavioral therapy is associated with the lowest societal costs. Cognitive behavioral therapy and CBT+SSRI are more cost-effective treatments for panic disorder with or without agoraphobia as compared to SSRI only.

Assessment of methylphenidate-induced changes in binding of continuously infused [(11)C]-raclopride in healthy human subjects: correlation with subjective effects.

RATIONALE: The dopaminergic system has been implicated in the pathogenesis and treatment of a variety of neuropsychiatric disorders. It has been shown that information on endogenous dopamine (DA) release can be obtained noninvasively by combining positron emission tomography with a dopaminergic challenge. This approach is based on the assumption that an injected radiolabeled ligand competes with the neurotransmitter for the same receptor. Increases in DA release will therefore result in a decreased binding of the radioligand. OBJECTIVES: We investigated the effect of the DA reuptake blocker methylphenidate (MP) on the binding of the D(2) receptor ligand [(11)C]-raclopride (RAC). METHODS: The effect of a 0.25 mg/kg intravenous dose of MP was studied in six healthy volunteers. RAC was administered as a bolus followed by constant infusion, and subjective effects were assessed using verbal rating scales. RESULTS: Control scans without MP administration showed that the mean RAC binding reached stable values approximately 30 min after start of the infusion. MP administration induced a 24% decrease in RAC binding in the total striatum. Correlations were found between the MP-induced change in euphoria and the percent change in binding potential (DeltaBP) in the dorsal striatum and between baseline anxiety and DeltaBP in the dorsal and middle striatum. We also found a negative correlation between baseline BP in the dorsal striatum and change in euphoria. CONCLUSIONS: Our results comply with previous findings, indicating the feasibility of the bolus infusion design combined with a relatively low MP dose to study dopaminergic (dys)function.

MR assessment of the normal position of the spinal cord in the spinal canal.

PURPOSE: To investigate intradural geometry, which strongly influences the effects of epidural spinal cord stimulation. METHODS: Axial MR images with turbo spin-echo were made of 26 healthy subjects at C-4 through C-6, T-5 and T-6, and T-11 and T-12, at T-11 and T-12 both in the supine and the prone position. Measurements were made of the dorsomedial and the ventromedial cerebrospinal fluid layer and the anteroposterior and transverse sizes of both the spinal cord and the dural sac. The samples of all variables were analyzed statistically. The distance between spinal and vertebral midline was also determined. RESULTS: The dorsal cerebrospinal fluid layer was 1.5 to 4.0 mm at C-4 through C-6 and 4.0 to 8.5 mm at T-5 and T-6. At T-11 it was 2.0 to 6.0 mm in the supine position and was increased by approximately 2.2 mm in the prone position. At T-12 these values were 1.5 to 4.5 mm and approximately 3.4 mm, respectively. Differences between the spinal and vertebral midline up to 1.5 to 2.0 mm occurred in approximately 40% of the images. CONCLUSIONS: Because there are variations of the dorsal cerebrospinal fluid layer among subjects by more than a factor of 2, and significant variations of the mediolateral position of the spinal cord, information on these parameters in patients will be essential for the optimal application of epidural spinal cord stimulation.